Discontinued — last reported Q3 '20

Finite-Lived Intangible Assets - Expected Amortization Expense (Year Four)

Merck & Co. Finite-Lived Intangible Assets - Expected Amortization Expense (Year Four) increased by 100.0% to $3.00B in Q4 2025 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement

SectionNon-Current Assets

CategoryProfitability

SignalContext dependent

VolatilityStable

First reportedQ1 2016

Last reportedQ3 2020

How to read this metric

A decrease suggests lower future non-cash charges, potentially boosting reported net income, while an increase reflects significant recent asset acquisitions.

Detailed definition

This represents the projected non-cash expense associated with the amortization of finite-lived intangible assets, such...

Peer comparison

Standard disclosure for pharmaceutical companies with significant M&A activity and R&D pipelines.

Metric ID: finite_lived_intangible_assets_amortization_year_4

Historical Data

2 periods

	Q4 '24	Q4 '25
Value	$1.50B	$3.00B
QoQ Change	—	+100.0%
YoY Change	—	+100.0%

Range$1.50B – $3.00B

Avg YoY Growth+100.0%

Median YoY Growth+100.0%

Frequently Asked Questions

What is Merck & Co.'s finite-lived intangible assets - expected amortization expense (year four)?: Merck & Co. (MRK) reported finite-lived intangible assets - expected amortization expense (year four) of $3.00B in Q4 2025.
What does finite-lived intangible assets - expected amortization expense (year four) mean?: The expected accounting expense for intangible assets in the fourth year from now.